Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia. (2008). Swiss Medical Weekly, 138(2930), 420-426. https://doi.org/10.4414/smw.2008.12120